{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"Percentage patients who experienced infections within 100 days post-transplant.","groups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO","id":"OG000","title":"Dose Level 1 (No Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"OG001","title":"Dose Level 2 (0.025 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"OG002","title":"Dose Level 3 (0.050 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"OG003","title":"Dose Level 4 (0.10 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"OG004","title":"Dose Level 5 (0.20 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"OG005","title":"Dose Level 6 (0.40 mg/kg/Day Campath)"}],"paramType":"NUMBER","populationDescription":"No subjects were enrolled onto groups beyond Dose level 1 because the dose escalation was not triggered over the course of the study.","reportingStatus":"POSTED","timeFrame":"100 days after transplant","title":"Evaluate the Risk/Incidence of Infections","type":"SECONDARY","unitOfMeasure":"percentage of participants"}